an anti-allergic drug targeting pi3k delta

Biology / Licensing
HEALTH
AN ANTI-ALLERGIC DRUG TARGETING
PI3K DELTA
Allergy is a growing health problem which concerns
millions of persons. Allergic asthma is a common disease,
ranging from benign to fatal disease. Some patients are
afflicted with steroid-dependent disease or treatmentrefractory disease. Novel agents are needed both for the
treatment of acute asthma and for regular therapy. While
novel agents are currently undergoing clinical trials there
still remains a significant unmet medical need in this
situation.
DESCRIPTION
PI3Kinase delta is an enzyme expressed by few cell
types including human basophils, a type of white blood
cell involved in allergy.
We have developed an inhibitor of PI3Kinase delta which
potently inhibits degranulation of stimulated normal
human basophils and protects mice developing albumininduced allergic asthma.
This treatment was well tolerated when administred over
a period of several weeks and was associated with a significant reduction in the pulmonary cellular inflammatory
infiltrate.
ADVANTAGES / NOVELTY
STAGE OF DEVELOPMENT
•
The PI3Kinase inhibitor which we have developed has
shown significant preclinical activity with normal human
stimulated basophils and in a preclinical mouse models
of allergic asthma.
Non regulatory chronic exposure for periods up to 4 weeks
showed no sign of toxicity.
Future development will include regulatory preclinical
toxicity before proceeding to a first in man study in patients
with severe asthma.
•
•
•
•
Targeted therapy
Excellent tolerance
Bioavailable by oral or intravenous route
Simple and low-cost synthesis
APPLICATIONS
•
Our primary indication is severe asthma, in
particular in patients relying on large daily doses of
steroids and/or refractory to therapy. Efficacy will be
measured by spirometric examinations.
Secondary indications include other manifestation
of allergy, including cutaneous and mucosal
manifestations.
INTELLECTUAL PROPERTY
Patent pending in PCT
Priority date: April 5th, 2013 (FR1353091)
COLLABORATION TYPE
PULSALYS looks for industrial partners and offers to
grant patent license.
RESEARCH TEAM
Pr Charles DUMONTET
Centre de Recherche en Cancérologie de Lyon UMR
INSERM 1052, CNRS 5286
INSERM, CNRS, UCBL, Centre Léon Bérard
PULSALYS
47, bd du 11 novembre 1918
69625 Villeurbanne Cedex
www.pulsalys.fr
Daphné THOMAS
Tel. +33 (0)4 26 23 56 78
[email protected]